Recent advances in high-throughput sequencing (next-generation sequencing) technology have made it possible to detect precise mutations associated with AML, not only for the highly sensitive detection of molecular measurable residual disease (MRD) after chemotherapy but also for the detection of mutations at loci that can determine the prognosis of the disease, such as FLT3 and EVI1 (27). This evidence concerns the gene RUNX1 and acute myeloid leukemia.